RecruitingPhase 1NCT06452160
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Studying Epithelioid hemangioendothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BridGene Biosciences Inc.
- Intervention
- BGC515(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06452160 on ClinicalTrials.govOther trials for Epithelioid hemangioendothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07104331SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid HemangioendotheliomaSarcoma Alliance for Research through Collaboration
- RECRUITINGNCT06408441The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)Fondazione IRCCS Istituto Nazionale dei Tumori, Milano